Nephros (NEPH) Furnishes Q2 2025 Results via Exhibit 99.1 Release

Rhea-AI Filing Summary

Nephros, Inc. furnished a press release disclosing its second quarter 2025 financial results and included that press release as Exhibit 99.1 to this Form 8-K. The company explicitly stated the exhibit is furnished, not filed, and therefore is not subject to liability under Section 18 of the Exchange Act nor automatically incorporated by reference into other filings unless expressly stated. The report was signed on behalf of the registrant by the Chief Financial Officer.

Insights

Financial Analyst

Routine earnings disclosure; filing contains no financial figures itself.

The 8-K notifies investors that Nephros has furnished a press release reporting its Q2 2025 results via Exhibit 99.1. The filing itself contains no revenue, profit, or cash-flow figures, so immediate analytical conclusions cannot be drawn from this document alone. Investors and analysts must review the referenced press release for the substantive financial metrics. The company’s clear statement that the exhibit is "furnished, not filed" is a standard disclosure that limits certain legal exposures and clarifies incorporation status for subsequent filings.

Corporate Governance Expert

Governance procedure followed; disclosure is procedural rather than transformative.

The Form 8-K follows customary practice by furnishing a press release as an exhibit and stating its furnished (not filed) status. That distinction preserves the company’s disclosure control boundaries while ensuring investors have access to the results. Because the filing does not include the underlying financial statements or management commentary, it should be treated as a notification of disclosure rather than a standalone material update.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nephros (NEPH) disclose in this 8-K?

The company furnished a press release disclosing its second quarter 2025 financial results, provided as Exhibit 99.1.

Is the press release included in the filing "filed" with the SEC?

No. The company stated the press release is furnished, not filed, and therefore is not subject to Section 18 liability nor automatically incorporated by reference.

Does the 8-K include the actual financial numbers for Q2 2025?

No. The 8-K notifies that results were disclosed in the press release but does not itself include revenue, profit, or other financial figures.

Where can I find the financial details referenced in this 8-K?

Review Exhibit 99.1 (the press release) attached to the filing; the 8-K references that exhibit for the substantive financial information.

Who signed the Form 8-K for Nephros?

The filing was signed on behalf of the registrant by the company’s Chief Financial Officer, Judy Krandel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2025 - 04:15 PM Learn about SEC filing dates

false 0001196298 0001196298 2025-08-07 2025-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2025

NEPHROS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware		001-32288		13-3971809
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

380 Lackawanna Place, South Orange, New Jersey 07079

(Address of principal executive offices, including ZIP code)

(201) 343-5202
(Registrant’s telephone number, including area code)

n/a

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		NEPH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 7, 2025, Nephros, Inc. (the “Company”) issued a press release in which it disclosed its second quarter 2025 financial results. A copy of this press release is furnished herewith as Exhibit 99.1.

Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Nephros, Inc. Press Release, dated August 7, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	Nephros, Inc.
Dated: August 11, 2025	By:	/s/ Judy Krandel
		Judy Krandel
		Chief Financial Officer